SecBot SecBot
8-K ·Filed Nov 9, 2026

SPRB

SPRUCE BIOSCIENCES, INC.
BEARISH
Impact 5/10
Horizonweeks Processed7d 15h ago SEC0001193125-26-452707
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The BLA submission in December 2026 is the key binary catalyst; the widening net loss and cash burn rate of ~$8.6M per quarter suggest the company will need additional capital before potential approval. Monitor the BLA filing and FDA acceptance, as well as the Adrenyx distribution timeline and any further debt or equity financing.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+5
Entry
$49.34
T+0 close · Nov 9, 2026 · via day close
Latest settled
−14.37%
T+5 · $42.25
Vs SPY
−12.68%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $49.34entry
  2. T+1 · 7d ago −5.42%α −5.05% · $46.67
  3. T+5 · 17h ago −14.37%α −12.68% · $42.25
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

The BLA submission for TA-ERT remains on track for December 2026, and the company amended its Avenue loan to increase Tranche 2 availability to $15M and extended the interest-only period. The separation of the CRHX-101 program into Adrenyx Biosciences with a $5M initial note and planned distribution to shareholders is a strategic restructuring, but the widening net loss and cash burn of $24M in the quarter are the dominant financial facts.

Key Financial Metrics

Revenue
$0.00
est $0.00

Key Facts

  • R&D expenses rose to $18.1M in Q3 2026 from $5.0M in Q3 2025, driven by TA-ERT manufacturing and clinical costs
  • Cash and equivalents $87.7M at Sep 30, 2026, down from $96.3M at Jun 30, 2026; cash runway into H2 2027
  • BLA submission for TA-ERT remains on track for December 2026 seeking accelerated approval for MPS IIIB
  • Avenue Loan Agreement amended to increase Tranche 2 to $15M and extend interest-only period through March 2027
  • CRHX-101 program separated into Adrenyx Biosciences subsidiary; $5M initial convertible note issued; planned stock distribution to SPRB shareholders in H1 2027

Financial Impact

Net loss of $24.0M in Q3 2026, cash burn of ~$8.6M from Q2 2026; EPS miss of $-8.51 vs $-5.51 consensus

net lossepscashr&d expenses

Risk Factors

  • BLA submission for TA-ERT may be delayed or rejected by FDA
  • Cash runway only into H2 2027; additional capital likely needed before potential commercial launch
  • EPS miss of 54% vs consensus indicates higher-than-expected operating costs
  • Separation of CRHX-101 into Adrenyx may not close as planned or may be taxable to shareholders

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
93% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-452707
Document: sprb-20261109.htm0001193125-26-452707
Document: 0001193125-26-452707-index-headers.html0001193125-26-452707
Document: 0001193125-26-452707-index.html0001193125-26-452707
Document: 0001193125-26-452707.txt0001193125-26-452707
8-K Data (Synthetic)0001193125-26-452707

US Market Status

Market Closed · Opens in 9h 29m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026